In response to the COVID-19 outbreak, A4P Bio Logistics has collaborated with Wren Healthcare to offer a one-stop solution for CROs, sponsors, and study sites to support the continuation of clinical trial studies through home nursing and direct-to-patient IMP and sample logistics. It has become increasingly difficult for patients to attend study sites, and our homecare solution allows studies to continue by taking the trial to the patient.
email tim.davies@a4pbio.com to find out how we can support through home nursing and our network of DTP logistic services.
Cambridge and Inverness, UK, 30th April 2020: TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with ODx (ODx Innovations Ltd), a company committed to developing a system for assessing urinary tract infections (UTIs). The collaboration is focussed on bringing ODx’ system to market through TTP’s Desktop Biology service.
The ODx system offers the potential to revolutionise the turnaround time for the assessment of suspected UTIs, reduce the use of antibiotics and provider faster access to optimal antimicrobial therapy.…
Cambridge, UK, 29 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.
Horizon’s OncoSpan range now includes formalin-fixed, paraffin-embedded (FFPE) and cell-free DNA (cfDNA) formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its well-…
Cambridge, UK: In vitro fertilisation (IVF) treatment is now a global affair which involves patients, fertility clinics, embryologists and transportation specialists. Each country has different legislation relating to fertility treatments, and with many patients now finding themselves seeking IVF in a country which supports their specific needs, it is crucial to securely and reliably transport the invaluable frozen eggs, sperms or embryos from one fertility clinic to another for further treatment cycles.
A patient was looking for a specialist courier to manage the transportation of frozen…
One Nucleus adds power and influence as senior AstraZeneca executive, Penny James joins the region’s life science membership organisation’s Board
Cambridge, UK: 28 April 2020: One Nucleus, the Cambridge based not-for-profit membership organisation for the East of England-London life sciences cluster, is delighted to announce the appointment of Penny James as a Non-Executive Director. Penny is Chief Operating Officer, Biopharmaceuticals R&D at AstraZeneca, a role she took up in February 2019.
Penny has 25 years’ experience working in pharmaceutical and chemical industries, having…
Cambridge, 27th April 2020: The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. The additional funding will further enhance the ability of the Babraham Research Campus to drive innovation in early science concepts and nurture new life science companies within the Cambridge cluster.
First launched in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures by giving access to appropriate short-term open access laboratory and…
Cambridge, UK: Biocair, a specialist logistics company, has recently managed several urgent large-scale shipments of COVID-19 related protective equipment. The company is also supporting many companies and agencies with the swift transportation of testing kits, diagnostic specimens and medical devices.
The successful time-sensitive transportation of these materials requires expertise and experience in the global life sciences supply chain. Speaking about the role Biocair plays in the life sciences supply chain, Giuseppe Tricarico, Business Development Director, comments that “since the global…
Cambridge, UK, 22 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that its cGMP-compliant CHOSOURCE™ platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s pharmaceutical-grade, stable Chinese Hamster Ovary (CHO) cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, enabling Immutep and Batavia Biosciences to reach an important…
21 April 2020 | The UK Government has announced a ground-breaking new fund that will provide matched financing to UK start-ups and scale-ups.
Taylor Wessing played a leading role in advising the UK Government on the new fund, delivering an unprecedented funding solution in an expedited timeframe.
Angus Miln, partner and head of Taylor Wessing's Corporate Technology group, worked alongside Adrian Rainey and Adam Thatcher from Goodwin Proctor, and Aaron Archer from Cooley LLP and Ylan Steiner from Orrick, Herrington & Sutcliffe LLP.
Commenting on the project, Angus Miln…